| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11033773 | Gene | 2018 | 25 Pages |
Abstract
CYP2C19*2 reduced the antiplatelet potency of clopidogrel and increased the risk of HTPR, while CRISPLD1 rs12115090 A>C polymorphism increased the antiplatelet potency of clopidogrel. Genetic tests, especially for CYP2C19*2 are recommended in Han Chinese CAD patients before using of clopidogrel.
Keywords
GOFHTPRSNPsACSLOFPRIDAPTMACEPCILoss-of-functionGain of functioncoronary artery diseasedual antiplatelet therapyLoading dosePCR-RFLPAcute coronary syndromeCADpercutaneous coronary interventionhigh on-treatment platelet reactivitySingle nucleotide polymorphismspolymerase chain reaction-restriction fragment length polymorphism
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Jie-Ya Wang, Yan-Jiao Zhang, He Li, Xiao-Lei Hu, Mu-Peng Li, Pei-Yuan Song, Qi-Lin Ma, Li-Ming Peng, Xiao-Ping Chen,